Fig. 4From: Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real worldSARS-CoV-2 NTAb profile kinetics including antibody level and seropositive rate in the volunteers in Shenzhen, China. The group inoculation of two doses of BBIBP-CorV vaccines with a four-weeks interval (A). The group only inoculation of one dose of BBIBP-CorV vaccine (B). The group inoculation of two doses of BBIBP-CorV vaccines with a strict four-weeks interval and the volunteers engaged the dynamic SARS-CoV-2 NTAb monitoring from before inoculation to a half of year post two-vaccinations (n = 37) (C)Back to article page